<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663871</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19060029</org_study_id>
    <secondary_id>2P01HL040962</secondary_id>
    <secondary_id>R01AT004699</secondary_id>
    <nct_id>NCT00663871</nct_id>
  </id_info>
  <brief_title>Evaluating the Effects of Omega-3 Fatty Acids on Heart Disease and Behavior</brief_title>
  <official_title>BioBehavioral Studies of Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Omega-3 fatty acids are a certain kind of fish fat that has recently been shown to have&#xD;
      health benefits. This study will examine the effectiveness of fish oil supplementation for&#xD;
      reducing the early signs of heart disease risk and for improving mood, impulsivity, and anger&#xD;
      levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease (CVD) is a broad term that includes diseases that affect the heart and&#xD;
      blood vessels, including coronary heart disease, heart failure, high blood pressure, stroke&#xD;
      and vascular dementia. CVD is the leading cause of death in the United States, resulting in&#xD;
      700,000 deaths each year. Preliminary research has shown that increased consumption of fish,&#xD;
      specifically the omega-3 fatty acids found in fish oil, has beneficial effects in people with&#xD;
      CVD. Fish oil may also have positive effects on the psychological health and well-being of&#xD;
      people with psychiatric disorders. However, more research is needed to confirm the positive&#xD;
      physical and psychological effects of fish oil in healthy adults. The purpose of this study&#xD;
      is to explore potentail effects of fish oil supplementation on CVD mechanisms and risk&#xD;
      markers, and on depressive symptoms, antagonistic disposition, and levels of impulsivity and&#xD;
      aggression.&#xD;
&#xD;
      This study will enroll healthy adults who habitually consume low quantities of long-chain&#xD;
      omega-3 fatty acids. Participants will be randomly assigned to receive either fish oil&#xD;
      supplements or placebo on a daily basis for 4 months. Study visits will occur at baseline and&#xD;
      Months 2 and 4. At the baseline and Month 4 visits, participants will undergo the following&#xD;
      measures as primary study aims: blood collection for inflammatory markers; heart rate and&#xD;
      variability measurements; and interviews, psychological tests, and questionnaires to assess&#xD;
      mood, disposition, impulsivity, and aggression.&#xD;
&#xD;
      As secondary aims, we will test for any effects of fish oil on cognitive performance and, if&#xD;
      a main effect on inflammatory markers is found, we will test for moderation by select genetic&#xD;
      polymorphisms.&#xD;
&#xD;
      As an exploratory aim, we will test for any effects of fish oil on structural or functional&#xD;
      brain imaging. (This exploratory aim was mistakenly listed as a secondary aim at the time of&#xD;
      trial registration.)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating Serum Interleukin-6 (IL-6)</measure>
    <time_frame>Baseline and Month 4</time_frame>
    <description>Systemic inflammation: fasting serum Interleukin-6 (IL-6)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive Protein (CRP)</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>fasting serum C-reactive protein (CRP) in milligrams per liter (mg/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative Affect</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>Negative affect questions adapted from the Positive and Negative Affect Schedule - Expanded Form administered via ecological momentary assessment. The minimum value is 1, and the maximum value is 6. A higher score are worse (more negative affect).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impulsivity</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>Barratt Impulsiveness Scale. The minimum value is 34, and the maximum value is 120. A higher score suggests a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aggression</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>Bus-Perry Aggression Questionnaire. The minimum value is 14, and the maximum value is 53. A higher score suggests a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hostility, Barefoot Score</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>The 27-item Barefoot Hostility Scale. The minimum value is 1, and the maximum value is 30. A higher score suggests a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trait Anger</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>State-Trait Anger Expression Inventory. The minimum value is 10, and the maximum value is 40. A higher score suggests a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anger Expression</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>State-Trait Anger Expression Inventory. The minimum value is 0, and the maximum value is 72. A higher score suggests a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type A, Total Score</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>Structured Interview - Type A Behavior Pattern using the Interpersonal Hostility Assessment Technique (IHAT). The minimum value is 0, and the maximum value is 12. A higher score suggests a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Successive Difference in Inter-beat Intervals Natural Log Transformed Paced Respiration</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>Mean successive difference in inter-beat intervals natural log transformed paced respiration in milliseconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High Frequency (.12 to .40 Hz) Heart Rate Variability Natural Log Transformed Paced Respiration</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>High frequency (.12 to .40 Hz) heart rate variability natural log transformed paced respiration in Hertz units (Hz)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Power (0 to .40 Hz) Heart Rate Variability Natural Log Transformed Paced Respiration</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>Total power (0 to .40 Hz) heart rate variability natural log transformed paced respiration in Hertz (Hz) units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Successive Difference in Inter-beat Intervals Natural Log Transformed Unpaced Respiration</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>Mean successive difference in inter-beat intervals natural log transformed unpaced respiration in milliseconds (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High Frequency (.12 to .40 Hz) Heart Rate Variability Natural Log Transformed Unpaced Respiration</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>High frequency (.12 to .40 Hz) heart rate variability natural log transformed unpaced respiration in Hertz (Hz) units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Power (0 to .40 Hz) Heart Rate Variability Natural Log Transformed Unpaced Respiration</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>Total power (0 to .40 Hz) heart rate variability natural log transformed unpaced respiration in Hertz (Hz) units</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Executive Function</measure>
    <time_frame>Baseline and Month 4</time_frame>
    <description>Executive function was comprised of trail making B - A time, digit span forward and digit span backward completions. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Learning / Episodic Memory</measure>
    <time_frame>Baseline and Month 4</time_frame>
    <description>Learning/episodic memory was comprised of d' from the four word memory task and the average performance across all trials of the Rey auditory verbal learning test. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor Speed</measure>
    <time_frame>Baseline and Month 4</time_frame>
    <description>Psychomotor speed was comprised of trail making A time, Stroop word-only time and color-only time. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid Intelligence</measure>
    <time_frame>Baseline and Month 4</time_frame>
    <description>This outcome was based upon matrix reasoning task raw score, block design task raw score and spatial span forward raw score. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderation of Effects of Fish Oil on Inflammatory Markers by Select Genetic Polymorphisms</measure>
    <time_frame>Measured at Month 4</time_frame>
    <description>Circulating serum concentrations of IL6 and CRP before and after supplementation with fish oil or placebo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Structural &amp; Functional MRI</measure>
    <time_frame>Baseline and month 4</time_frame>
    <description>Measures of brain structure and function from magnetic resonance imaging</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Mood Disorders</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take fish oil supplements daily for 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take soybean oil (placebo) supplements daily for 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
    <arm_group_label>Fish Oil</arm_group_label>
    <other_name>Omega-3 Life Formula (PharmaOmega)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soybean Oil (Placebo)</intervention_name>
    <description>Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Currently employed at least 25 hours a week, but does not regularly work the third&#xD;
             shift (i.e., night shift)&#xD;
&#xD;
          -  English is primary language&#xD;
&#xD;
          -  Consumes less than 300 mg/day of long-chain omega-3 fatty acids.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious allergy to fish (e.g., anaphylaxis, bronchospasm, serious skin reaction)&#xD;
&#xD;
          -  History of atherosclerotic disease (e.g., myocardial infarction) or treatment of&#xD;
             angina or claudication (e.g., angioplasty)&#xD;
&#xD;
          -  Reported history of schizophrenia or bipolar disorder&#xD;
&#xD;
          -  Long-term hepatitis&#xD;
&#xD;
          -  Kidney failure&#xD;
&#xD;
          -  Stroke or other neurological disorder&#xD;
&#xD;
          -  Lung disease requiring drug treatment&#xD;
&#xD;
          -  Stage 2 high blood pressure, defined as systolic blood pressure of 160 mm Hg or&#xD;
             greater and diastolic blood pressure of 100 mm Hg or greater&#xD;
&#xD;
          -  Alcohol consumption of more than five drinks per day each week (i.e., more than 35&#xD;
             alcoholic drinks each week)&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Currently taking any cardiovascular, psychotropic, glucocorticoid, lipid-lowering,&#xD;
             insulin, or weight loss medications&#xD;
&#xD;
          -  Currently taking fish oil supplements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew F. Muldoon, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Muldoon MF, Ryan CM, Yao JK, Conklin SM, Manuck SB. Long-chain omega-3 fatty acids and optimization of cognitive performance. Mil Med. 2014 Nov;179(11 Suppl):95-105. doi: 10.7205/MILMED-D-14-00168. Review.</citation>
    <PMID>25373092</PMID>
  </reference>
  <results_reference>
    <citation>Leckie RL, Lehman DE, Gianaros PJ, Erickson KI, Sereika SM, Kuan DCH, Manuck SB, Ryan CM, Yao JK, Muldoon MF. The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial. Psychol Med. 2020 Oct;50(14):2425-2434. doi: 10.1017/S0033291719002617. Epub 2019 Oct 4.</citation>
    <PMID>31581959</PMID>
  </results_reference>
  <results_reference>
    <citation>Muldoon MF, Laderian B, Kuan DC, Sereika SM, Marsland AL, Manuck SB. Fish oil supplementation does not lower C-reactive protein or interleukin-6 levels in healthy adults. J Intern Med. 2016 Jan;279(1):98-109. doi: 10.1111/joim.12442. Epub 2015 Oct 26.</citation>
    <PMID>26497831</PMID>
  </results_reference>
  <results_reference>
    <citation>Ginty AT, Muldoon MF, Kuan DCH, Schirda B, Kamarck TW, Jennings JR, Manuck SB, Gianaros PJ. Omega-3 Supplementation and the Neural Correlates of Negative Affect and Impulsivity: A Double-Blind, Randomized, Placebo-Controlled Trial in Midlife Adults. Psychosom Med. 2017 Jun;79(5):549-556. doi: 10.1097/PSY.0000000000000453.</citation>
    <PMID>28121722</PMID>
  </results_reference>
  <results_reference>
    <citation>Cipollina C, Salvatore SR, Muldoon MF, Freeman BA, Schopfer FJ. Generation and dietary modulation of anti-inflammatory electrophilic omega-3 fatty acid derivatives. PLoS One. 2014 Apr 15;9(4):e94836. doi: 10.1371/journal.pone.0094836. eCollection 2014.</citation>
    <PMID>24736647</PMID>
  </results_reference>
  <results_reference>
    <citation>Muldoon MF, Ryan CM, Sheu L, Yao JK, Conklin SM, Manuck SB. Serum phospholipid docosahexaenonic acid is associated with cognitive functioning during middle adulthood. J Nutr. 2010 Apr;140(4):848-53. doi: 10.3945/jn.109.119578. Epub 2010 Feb 24.</citation>
    <PMID>20181791</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu JC, Conklin SM, Manuck SB, Yao JK, Muldoon MF. Long-chain omega-3 fatty acids and blood pressure. Am J Hypertens. 2011 Oct;24(10):1121-6. doi: 10.1038/ajh.2011.120. Epub 2011 Jul 14.</citation>
    <PMID>21753804</PMID>
  </results_reference>
  <results_reference>
    <citation>Conklin SM, Harris JI, Manuck SB, Yao JK, Hibbeln JR, Muldoon MF. Serum omega-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers. Psychiatry Res. 2007 Jul 30;152(1):1-10. Epub 2007 Mar 23.</citation>
    <PMID>17383013</PMID>
  </results_reference>
  <results_reference>
    <citation>Conklin SM, Gianaros PJ, Brown SM, Yao JK, Hariri AR, Manuck SB, Muldoon MF. Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults. Neurosci Lett. 2007 Jun 29;421(3):209-12. Epub 2007 Jun 2.</citation>
    <PMID>17574755</PMID>
  </results_reference>
  <results_reference>
    <citation>Conklin SM, Manuck SB, Yao JK, Flory JD, Hibbeln JR, Muldoon MF. High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom Med. 2007 Dec;69(9):932-4. Epub 2007 Nov 8.</citation>
    <PMID>17991818</PMID>
  </results_reference>
  <results_reference>
    <citation>Conklin SM, Runyan CA, Leonard S, Reddy RD, Muldoon MF, Yao JK. Age-related changes of n-3 and n-6 polyunsaturated fatty acids in the anterior cingulate cortex of individuals with major depressive disorder. Prostaglandins Leukot Essent Fatty Acids. 2010 Feb-Mar;82(2-3):111-9. doi: 10.1016/j.plefa.2009.12.002. Epub 2010 Jan 8.</citation>
    <PMID>20060277</PMID>
  </results_reference>
  <results_reference>
    <citation>Muldoon MF, Erickson KI, Goodpaster BH, Jakicic JM, Conklin SM, Sekikawa A, Yao JK, Manuck SB. Concurrent physical activity modifies the association between n3 long-chain fatty acids and cardiometabolic risk in midlife adults. J Nutr. 2013 Sep;143(9):1414-20. doi: 10.3945/jn.113.174078. Epub 2013 Jul 24.</citation>
    <PMID>23884386</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <results_first_submitted>February 11, 2021</results_first_submitted>
  <results_first_submitted_qc>April 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2021</results_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Stephen Manuck</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Fish Oil</keyword>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Affect</keyword>
  <keyword>Depression</keyword>
  <keyword>Anger</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Impulsivity</keyword>
  <keyword>Aggression</keyword>
  <keyword>Cognition</keyword>
  <keyword>Behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fish Oil</title>
          <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fish Oil</title>
          <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
            <count group_id="B2" value="138"/>
            <count group_id="B3" value="272"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="268"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Circulating Serum Interleukin-6 (IL-6)</title>
        <description>Systemic inflammation: fasting serum Interleukin-6 (IL-6)</description>
        <time_frame>Baseline and Month 4</time_frame>
        <population>11 participants had chronic inflammatory conditions at baseline and were excluded, leaving 129 in fish oil and 132 in placebo groups.&#xD;
The 17 subjects who did not finish the study were retained through use of single-imputation analysis. Any subject missing both baseline and 4-month data could not be retained. TThis applied to 2 fish oil and 1 placebo participants for IL-6, leaving 127 and 131, respectively in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Serum Interleukin-6 (IL-6)</title>
          <description>Systemic inflammation: fasting serum Interleukin-6 (IL-6)</description>
          <population>11 participants had chronic inflammatory conditions at baseline and were excluded, leaving 129 in fish oil and 132 in placebo groups.&#xD;
The 17 subjects who did not finish the study were retained through use of single-imputation analysis. Any subject missing both baseline and 4-month data could not be retained. TThis applied to 2 fish oil and 1 placebo participants for IL-6, leaving 127 and 131, respectively in the analysis population.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.465" upper_limit="1.79"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.60" upper_limit="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.60" upper_limit="1.72"/>
                    <measurement group_id="O2" value="0.81" lower_limit="0.53" upper_limit="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C-reactive Protein (CRP)</title>
        <description>fasting serum C-reactive protein (CRP) in milligrams per liter (mg/L)</description>
        <time_frame>baseline and month 4</time_frame>
        <population>11 participants had chronic inflammatory conditions at baseline and were excluded, leaving 129 in fish oil and 132 in placebo groups.&#xD;
The 17 subjects who did not finish the study were retained through use of single-imputation analysis. Any subject missing both baseline and 4-month data could not be retained. This applied to 4 fish oil and 3 placebo participants for CRP, leaving 125 and 129, respectively, in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (CRP)</title>
          <description>fasting serum C-reactive protein (CRP) in milligrams per liter (mg/L)</description>
          <population>11 participants had chronic inflammatory conditions at baseline and were excluded, leaving 129 in fish oil and 132 in placebo groups.&#xD;
The 17 subjects who did not finish the study were retained through use of single-imputation analysis. Any subject missing both baseline and 4-month data could not be retained. This applied to 4 fish oil and 3 placebo participants for CRP, leaving 125 and 129, respectively, in the analysis population.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit=".043" upper_limit="2.17"/>
                    <measurement group_id="O2" value="0.67" lower_limit="0.30" upper_limit="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit=".042" upper_limit="2.02"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.33" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Negative Affect</title>
        <description>Negative affect questions adapted from the Positive and Negative Affect Schedule - Expanded Form administered via ecological momentary assessment. The minimum value is 1, and the maximum value is 6. A higher score are worse (more negative affect).</description>
        <time_frame>baseline and month 4</time_frame>
        <population>All randomized participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Affect</title>
          <description>Negative affect questions adapted from the Positive and Negative Affect Schedule - Expanded Form administered via ecological momentary assessment. The minimum value is 1, and the maximum value is 6. A higher score are worse (more negative affect).</description>
          <population>All randomized participants were analyzed.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" lower_limit="1.23" upper_limit="2.42"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.28" upper_limit="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.20" upper_limit="2.33"/>
                    <measurement group_id="O2" value="1.59" lower_limit="1.21" upper_limit="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.92</p_value>
            <p_value_desc>The model included effects of treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time. The Negative Affect scores were categorized by quartiles of the baseline measures.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized Linear Mixed Modeling was used with a multinomial distribution with cumulative link.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Impulsivity</title>
        <description>Barratt Impulsiveness Scale. The minimum value is 34, and the maximum value is 120. A higher score suggests a worse outcome.</description>
        <time_frame>baseline and month 4</time_frame>
        <population>All randomized participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Impulsivity</title>
          <description>Barratt Impulsiveness Scale. The minimum value is 34, and the maximum value is 120. A higher score suggests a worse outcome.</description>
          <population>All randomized participants were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.44" spread="8.53"/>
                    <measurement group_id="O2" value="59.57" spread="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.41" spread="9.27"/>
                    <measurement group_id="O2" value="59.38" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.86</p_value>
            <p_value_desc>The model included effects of treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aggression</title>
        <description>Bus-Perry Aggression Questionnaire. The minimum value is 14, and the maximum value is 53. A higher score suggests a worse outcome.</description>
        <time_frame>baseline and month 4</time_frame>
        <population>All randomized participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Aggression</title>
          <description>Bus-Perry Aggression Questionnaire. The minimum value is 14, and the maximum value is 53. A higher score suggests a worse outcome.</description>
          <population>All randomized participants were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.14" spread="8.32"/>
                    <measurement group_id="O2" value="27.55" spread="7.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.75" spread="8.90"/>
                    <measurement group_id="O2" value="27.46" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.63</p_value>
            <p_value_desc>The model included effects of treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.57</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hostility, Barefoot Score</title>
        <description>The 27-item Barefoot Hostility Scale. The minimum value is 1, and the maximum value is 30. A higher score suggests a worse outcome.</description>
        <time_frame>baseline and month 4</time_frame>
        <population>All randomized participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Hostility, Barefoot Score</title>
          <description>The 27-item Barefoot Hostility Scale. The minimum value is 1, and the maximum value is 30. A higher score suggests a worse outcome.</description>
          <population>All randomized participants were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.58" spread="6.52"/>
                    <measurement group_id="O2" value="12.54" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.30" spread="6.53"/>
                    <measurement group_id="O2" value="12.58" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.50</p_value>
            <p_value_desc>The model included effects of treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trait Anger</title>
        <description>State-Trait Anger Expression Inventory. The minimum value is 10, and the maximum value is 40. A higher score suggests a worse outcome.</description>
        <time_frame>baseline and month 4</time_frame>
        <population>All randomized participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Trait Anger</title>
          <description>State-Trait Anger Expression Inventory. The minimum value is 10, and the maximum value is 40. A higher score suggests a worse outcome.</description>
          <population>All randomized participants were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.07" spread="3.69"/>
                    <measurement group_id="O2" value="16.01" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.39" spread="3.32"/>
                    <measurement group_id="O2" value="15.03" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.25</p_value>
            <p_value_desc>The model included effects of treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anger Expression</title>
        <description>State-Trait Anger Expression Inventory. The minimum value is 0, and the maximum value is 72. A higher score suggests a worse outcome.</description>
        <time_frame>baseline and month 4</time_frame>
        <population>All randomized participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Anger Expression</title>
          <description>State-Trait Anger Expression Inventory. The minimum value is 0, and the maximum value is 72. A higher score suggests a worse outcome.</description>
          <population>All randomized participants were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.73" spread="8.86"/>
                    <measurement group_id="O2" value="24.50" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.83" spread="8.63"/>
                    <measurement group_id="O2" value="23.25" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.52</p_value>
            <p_value_desc>The model included effects of treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.83</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Type A, Total Score</title>
        <description>Structured Interview - Type A Behavior Pattern using the Interpersonal Hostility Assessment Technique (IHAT). The minimum value is 0, and the maximum value is 12. A higher score suggests a worse outcome.</description>
        <time_frame>baseline and month 4</time_frame>
        <population>All randomized participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Type A, Total Score</title>
          <description>Structured Interview - Type A Behavior Pattern using the Interpersonal Hostility Assessment Technique (IHAT). The minimum value is 0, and the maximum value is 12. A higher score suggests a worse outcome.</description>
          <population>All randomized participants were analyzed.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.5" upper_limit="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.52</p_value>
            <p_value_desc>The model included effects for treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time. The Type A personality scores were categorized by quartiles of the baseline measures.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized Linear Mixed Modeling was used with a multinomial distribution with cumulative link.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>2.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Successive Difference in Inter-beat Intervals Natural Log Transformed Paced Respiration</title>
        <description>Mean successive difference in inter-beat intervals natural log transformed paced respiration in milliseconds</description>
        <time_frame>baseline and month 4</time_frame>
        <population>One participant was excluded from the analysis due to missing both at baseline and 4-month data..</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Successive Difference in Inter-beat Intervals Natural Log Transformed Paced Respiration</title>
          <description>Mean successive difference in inter-beat intervals natural log transformed paced respiration in milliseconds</description>
          <population>One participant was excluded from the analysis due to missing both at baseline and 4-month data..</population>
          <units>ln(milliseconds)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="0.77"/>
                    <measurement group_id="O2" value="3.13" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" spread="0.83"/>
                    <measurement group_id="O2" value="3.08" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>The model included effects for treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>High Frequency (.12 to .40 Hz) Heart Rate Variability Natural Log Transformed Paced Respiration</title>
        <description>High frequency (.12 to .40 Hz) heart rate variability natural log transformed paced respiration in Hertz units (Hz)</description>
        <time_frame>baseline and month 4</time_frame>
        <population>One participant was excluded from the analysis due to missing both at baseline and 4-month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>High Frequency (.12 to .40 Hz) Heart Rate Variability Natural Log Transformed Paced Respiration</title>
          <description>High frequency (.12 to .40 Hz) heart rate variability natural log transformed paced respiration in Hertz units (Hz)</description>
          <population>One participant was excluded from the analysis due to missing both at baseline and 4-month data.</population>
          <units>ln(hertz)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="1.52"/>
                    <measurement group_id="O2" value="6.15" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" spread="1.66"/>
                    <measurement group_id="O2" value="6.13" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>The model included effects for treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time.</non_inferiority_desc>
            <p_value>0.16</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Power (0 to .40 Hz) Heart Rate Variability Natural Log Transformed Paced Respiration</title>
        <description>Total power (0 to .40 Hz) heart rate variability natural log transformed paced respiration in Hertz (Hz) units.</description>
        <time_frame>baseline and month 4</time_frame>
        <population>One participant was excluded from the analysis due to missing both at baseline and 4-month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Power (0 to .40 Hz) Heart Rate Variability Natural Log Transformed Paced Respiration</title>
          <description>Total power (0 to .40 Hz) heart rate variability natural log transformed paced respiration in Hertz (Hz) units.</description>
          <population>One participant was excluded from the analysis due to missing both at baseline and 4-month data.</population>
          <units>ln(hertz)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.02" spread="1.10"/>
                    <measurement group_id="O2" value="7.21" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="1.10"/>
                    <measurement group_id="O2" value="7.18" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>The model included effects for treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time.</non_inferiority_desc>
            <p_value>0.59</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Successive Difference in Inter-beat Intervals Natural Log Transformed Unpaced Respiration</title>
        <description>Mean successive difference in inter-beat intervals natural log transformed unpaced respiration in milliseconds (msec)</description>
        <time_frame>baseline and month 4</time_frame>
        <population>One participant was excluded from the analysis due to missing both at baseline and 4-month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Successive Difference in Inter-beat Intervals Natural Log Transformed Unpaced Respiration</title>
          <description>Mean successive difference in inter-beat intervals natural log transformed unpaced respiration in milliseconds (msec)</description>
          <population>One participant was excluded from the analysis due to missing both at baseline and 4-month data.</population>
          <units>ln(milliseconds)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="0.71"/>
                    <measurement group_id="O2" value="3.11" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" spread="0.71"/>
                    <measurement group_id="O2" value="3.03" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>The model included effects for treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time.</non_inferiority_desc>
            <p_value>0.35</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>High Frequency (.12 to .40 Hz) Heart Rate Variability Natural Log Transformed Unpaced Respiration</title>
        <description>High frequency (.12 to .40 Hz) heart rate variability natural log transformed unpaced respiration in Hertz (Hz) units</description>
        <time_frame>baseline and month 4</time_frame>
        <population>One participant was excluded from the analysis due to missing both at baseline and 4-month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>High Frequency (.12 to .40 Hz) Heart Rate Variability Natural Log Transformed Unpaced Respiration</title>
          <description>High frequency (.12 to .40 Hz) heart rate variability natural log transformed unpaced respiration in Hertz (Hz) units</description>
          <population>One participant was excluded from the analysis due to missing both at baseline and 4-month data.</population>
          <units>ln(hertz)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.37" spread="1.40"/>
                    <measurement group_id="O2" value="5.61" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="1.41"/>
                    <measurement group_id="O2" value="5.51" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>The model included effects for treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time.</non_inferiority_desc>
            <p_value>0.74</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Power (0 to .40 Hz) Heart Rate Variability Natural Log Transformed Unpaced Respiration</title>
        <description>Total power (0 to .40 Hz) heart rate variability natural log transformed unpaced respiration in Hertz (Hz) units</description>
        <time_frame>baseline and month 4</time_frame>
        <population>One participant in placebo group was excluded from the analysis due to missing both at baseline and 4-month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Power (0 to .40 Hz) Heart Rate Variability Natural Log Transformed Unpaced Respiration</title>
          <description>Total power (0 to .40 Hz) heart rate variability natural log transformed unpaced respiration in Hertz (Hz) units</description>
          <population>One participant in placebo group was excluded from the analysis due to missing both at baseline and 4-month data.</population>
          <units>ln(hertz)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.05" spread="0.98"/>
                    <measurement group_id="O2" value="7.13" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.98" spread="0.97"/>
                    <measurement group_id="O2" value="7.15" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>The model included effects for treatment (fish oil, placebo), time (baseline, post-intervention), and interaction terms of treatment with time.</non_inferiority_desc>
            <p_value>0.28</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Executive Function</title>
        <description>Executive function was comprised of trail making B - A time, digit span forward and digit span backward completions. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
        <time_frame>Baseline and Month 4</time_frame>
        <population>One participant in placebo group was excluded from the analysis due to missing both at baseline and 4-month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Executive Function</title>
          <description>Executive function was comprised of trail making B - A time, digit span forward and digit span backward completions. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
          <population>One participant in placebo group was excluded from the analysis due to missing both at baseline and 4-month data.</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.57"/>
                    <measurement group_id="O2" value="0.02" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.62"/>
                    <measurement group_id="O2" value="0.03" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Repeated Measures MANOVA</method>
            <param_type>standardized mean difference</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Learning / Episodic Memory</title>
        <description>Learning/episodic memory was comprised of d' from the four word memory task and the average performance across all trials of the Rey auditory verbal learning test. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
        <time_frame>Baseline and Month 4</time_frame>
        <population>One participant in placebo group was excluded from the analysis due to missing both at baseline and 4-month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Learning / Episodic Memory</title>
          <description>Learning/episodic memory was comprised of d' from the four word memory task and the average performance across all trials of the Rey auditory verbal learning test. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
          <population>One participant in placebo group was excluded from the analysis due to missing both at baseline and 4-month data.</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.87"/>
                    <measurement group_id="O2" value="-0.01" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.85"/>
                    <measurement group_id="O2" value="0.12" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Repeated Measures MANOVA</method>
            <param_type>standardized mean difference</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychomotor Speed</title>
        <description>Psychomotor speed was comprised of trail making A time, Stroop word-only time and color-only time. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
        <time_frame>Baseline and Month 4</time_frame>
        <population>One participant in placebo group was excluded from the analysis due to missing both at baseline and 4-month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Psychomotor Speed</title>
          <description>Psychomotor speed was comprised of trail making A time, Stroop word-only time and color-only time. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
          <population>One participant in placebo group was excluded from the analysis due to missing both at baseline and 4-month data.</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.63"/>
                    <measurement group_id="O2" value="-0.04" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.54"/>
                    <measurement group_id="O2" value="0.007" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Repeated Measures MANOVA</method>
            <param_type>standardized mean difference</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluid Intelligence</title>
        <description>This outcome was based upon matrix reasoning task raw score, block design task raw score and spatial span forward raw score. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
        <time_frame>Baseline and Month 4</time_frame>
        <population>One participant in placebo group was excluded from the analysis due to missing both at baseline and 4-month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid Intelligence</title>
          <description>This outcome was based upon matrix reasoning task raw score, block design task raw score and spatial span forward raw score. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.</description>
          <population>One participant in placebo group was excluded from the analysis due to missing both at baseline and 4-month data.</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.85"/>
                    <measurement group_id="O2" value="0.02" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.82"/>
                    <measurement group_id="O2" value="0.05" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Repeated Measures MANOVA</method>
            <method_desc>Repeated Measures MANOVA</method_desc>
            <param_type>Standardized mean difference</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moderation of Effects of Fish Oil on Inflammatory Markers by Select Genetic Polymorphisms</title>
        <description>Circulating serum concentrations of IL6 and CRP before and after supplementation with fish oil or placebo.</description>
        <time_frame>Measured at Month 4</time_frame>
        <population>This aim was conditional and was not completed per the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Moderation of Effects of Fish Oil on Inflammatory Markers by Select Genetic Polymorphisms</title>
          <description>Circulating serum concentrations of IL6 and CRP before and after supplementation with fish oil or placebo.</description>
          <population>This aim was conditional and was not completed per the protocol.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Structural &amp; Functional MRI</title>
        <description>Measures of brain structure and function from magnetic resonance imaging</description>
        <time_frame>Baseline and month 4</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <desc>Used pre-specified 9 item side effect questionnaire.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fish Oil</title>
          <description>Participants will take fish oil supplements daily for 4 months.&#xD;
Fish Oil: Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will take soybean oil (placebo) supplements daily for 4 months.&#xD;
Soybean Oil (Placebo): Participants will take 2 grams of soybean oil supplements on a daily basis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loose stool, bloating or gas pains</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fishy belch or after-taste</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="134"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew F. Muldoon, MD, MPH</name_or_title>
      <organization>University of Pittsburgh, Heart and Vascular Institute</organization>
      <phone>412-624-8798</phone>
      <email>mfm10@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

